Palbociclib in hormone-receptor-positive advanced breast cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer. METHODS: This phase 3 study involved 521 patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred. RESULTS: The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib-fulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo-fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo. CONCLUSIONS: Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an interim analysis reported PFS of 9.2 months with palbociclib-fulvestrant and 3.8 months with placebo-fulvestrant (hazard ratio 0.42)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
In the citing paper
“This study enrolled pre- and peri-menopausal patients, with benefit of the combination observed across groups.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationThe history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Cited by
Items 101–200 of 1,000
Chemotherapeutic agents for the treatment of metastatic breast cancer: An update
Abotaleb, M., Kubatka, P., Caprnda, M., Varghese, E., Zolakova, B., Zubor, P., Opatrilova, R., Kruzliak, P., Stefanicka, P., & Büsselberg, D. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.108 · Cited by 184
Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy
Knudsen, E. S., Pruitt, S. C., Hershberger, P. A., Witkiewicz, A. K., & Goodrich, D. W. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.03.005 · Cited by 185
“While CDK4/6 inhibitors elicit a profound impact on delaying the progression of ER+ metastatic breast cancer and have transformed the treatment of disease, veritably all patients ultimately progress on treatment [28, 29].”
BackgroundFinn, R. S., Crown, J. P., Ettl, J., Schmidt, M., Bondarenko, I. M., Lang, I., Pinter, T., Boer, K., Patel, R., Randolph, S., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0721-5 · Cited by 186
Self-citationSpring, L. M., Zangardi, M. L., Moy, B., & Bardia, A. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0142 · Cited by 178
Xu, B., Zhang, Q., Zhang, P., Hu, X., Li, W., Tong, Z., Sun, T., Teng, Y., Wu, X., Ouyang, Q., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01562-9 · Cited by 179
Harbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Bhattacharyya, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw139 · Cited by 176
Self-citationXu, L., Chu, Z., Wang, H., Cai, L., Tu, Z., Liu, H., Zhu, C., Shi, H., Pan, D., Pan, J., et al. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b00381 · Cited by 180
Finn, R. S., Boer, K., Bondarenko, I., Patel, R., Pinter, T., Schmidt, M., Shparyk, Y. V., Thummala, A., Voitko, N., Bananis, E., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05755-7 · Cited by 171
Thill, M., & Schmidt, M. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918793326 · Cited by 172
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
Wang, X., Zhao, S., Xin, Q., Zhang, Y., Wang, K., & Li, M. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00747-x · Cited by 163
Cottu, P., D'Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P.-E., Duhoux, F. P., Levy, C., Mouret-Reynier, M.-A., Dalenc, F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy448 · Cited by 173
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
Spring, L. M., Wander, S. A., Zangardi, M., & Bardia, A. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0769-3 · Cited by 170
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
Kuter, D. J. (2022) · Haematologica · doi:10.3324/haematol.2021.279512 · Cited by 184
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0467-2 · Cited by 168
An emerging generation of endocrine therapies in breast cancer: a clinical perspective
Patel, R. D., Klein, P., Tiersten, A., & Sparano, J. A. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00523-4 · Cited by 181
Malorni, L., Piazza, S., Ciani, Y., Guarducci, C., Bonechi, M., Biagioni, C., Hart, C. D., Verardo, R., Leo, A. D., & Migliaccio, I. (2016) · Oncotarget · doi:10.18632/oncotarget.12010 · Cited by 162
Tjan‐Heijnen, V. C. G., van Hellemond, I. E. G., Peer, P. G. M., Swinkels, A. C. P., Smorenburg, C. H., van der Sangen, M. J. C., Kroep, J. R., de Graaf, H., Honkoop, A. H., Erdkamp, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30600-9 · Cited by 172
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
Corona, S. P., & Generali, D. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s137783 · Cited by 157
Targeted therapy for breast cancer: An overview of drug classes and outcomes
Jacobs, A. T., Castaneda-Cruz, D. M., Rose, M. M., & Connelly, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115209 · Cited by 173
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
George, M. A., Qureshi, S., Omene, C. O., Toppmeyer, D., & Ganesan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693104 · Cited by 165
“In ER+ breast cancer, they work synergistically with anti-estrogen therapies such as aromatase inhibitors, Fulvestrant and tamoxifen (1, 2, 4, 7, 17, 18).”
BackgroundMills, J. N., Rutkovsky, A. C., & Giordano, A. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.04.009 · Cited by 152
Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG
Cordero, F. J., Huang, Z., Grenier, C., He, X., Hu, G., McLendon, R. E., Murphy, S. K., Hashizume, R., & Becher, O. J. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0389 · Cited by 157
Optimal management of hormone receptor positive metastatic breast cancer in 2016
Reinert, T., & Barrios, C. H. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015608993 · Cited by 169
Loibl, S., Turner, N. C., Ro, J., Cristofanilli, M., Iwata, H., Im, S., Masuda, N., Loi, S., André, F., Harbeck, N., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0072 · Cited by 165
Self-citationKalinsky, K., Diamond, J. R., Vahdat, L. T., Tolaney, S. M., Juric, D., O'Shaughnessy, J., Moroose, R. L., Mayer, I. A., Abramson, V. G., Goldenberg, D. M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.004 · Cited by 151
Ma, S., Tang, T., Probst, G., Konradi, A., Jin, C., Li, F., Gutkind, J. S., Fu, X.-D., & Guan, K.-L. (2022) · Nature Communications · doi:10.1038/s41467-022-28691-0 · Cited by 143
Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153
Alumkal, J. J., Sun, D., Lu, E., Beer, T. M., Thomas, G. V., Latour, E., Aggarwal, R., Cetnar, J., Ryan, C. J., Tabatabaei, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922207117 · Cited by 147
Endocrine treatment in breast cancer: Cure, resistance and beyond
Tryfonidis, K., Zardavas, D., Katzenellenbogen, B. S., & Piccart, M. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.008 · Cited by 153
Role of Hedgehog Signaling in Breast Cancer: Pathogenesis and Therapeutics
Galdo, N. A. R., Montero, Á. L., & Wertheimer, E. V. (2019) · Cells · doi:10.3390/cells8040375 · Cited by 154
“Tumors with positive hormone receptor status, characterized by upregulation of cyclin D1 and concurrent activation of cyclin-dependent kinases CDK4 and CDK6 [20], can also be treated with CDK4/CDK6 inhibitors palbociclib, ribociclib and abemaciclib.”
BackgroundMayer, E. L., Ren, Y., Wagle, N., Mahtani, R. L., Ma, C. X., DeMichele, A. M., Cristofanilli, M., Meisel, J. L., Miller, K. D., Abdou, Y. G., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01940 · Cited by 151
Self-citationICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Patel, H., Periyasamy, M., Sava, G. P., Bondke, A., Slafer, B. W., Kroll, S. H. B., Barbazanges, M., Starkey, R., Ottaviani, S., Harrod, A., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0847 · Cited by 148
The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer?
Bhateja, P., Cherian, M. A., Majumder, S., & Ramaswamy, B. (2019) · Cancers · doi:10.3390/cancers11081126 · Cited by 152
Pearson, A., Proszek, P., Pascual, J., Fribbens, C., Shamsher, M. K., Kingston, B., O'Leary, B., Herrera-Abreu, M. T., Cutts, R. J., Garcia-Murillas, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4044 · Cited by 136
Self-citationUras, I. Z., Walter, G. J., Scheicher, R., Bellutti, F., Prchal‐Murphy, M., Tigan, A.-S., Valent, P., Heidel, F. H., Kubicek, S., Scholl, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683581 · Cited by 149
Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies
Murphy, C. G., & Dickler, M. N. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0121 · Cited by 142
Lalami, Y., & Klastersky, J. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.005 · Cited by 150
Guarducci, C., Bonechi, M., Benelli, M., Biagioni, C., Boccalini, G., Romagnoli, D., Verardo, R., Schiff, R., Osborne, C. K., Angelis, C. D., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0092-4 · Cited by 153
DeMichele, A. M., Cristofanilli, M., Brufsky, A., Liu, X., Mardekian, J., McRoy, L., Layman, R. M., Emir, B., Torres, M. A., Rugo, H. S., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01409-8 · Cited by 144
Self-citationOvercoming Endocrine Resistance in Hormone Receptor–Positive Breast Cancer
Al-Fakeeh, A., & Brezden‐Masley, C. (2018) · Current Oncology · doi:10.3747/co.25.3752 · Cited by 140
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment
Pasha, N., & Turner, N. C. (2021) · Nature Cancer · doi:10.1038/s43018-021-00229-1 · Cited by 143
Self-citationPatten, D. K., Corleone, G., Győrffy, B., Perone, Y., Slaven, N., Barozzi, I., Erdős, E., Saiakhova, A., Goddard, K., Vingiani, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0091-x · Cited by 131
Clark, A. S., Karasic, T. B., DeMichele, A. M., Vaughn, D. J., O’Hara, M. H., Perini, R. F., Zhang, P. J., Lal, P., Feldman, M. D., Gallagher, M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4701 · Cited by 144
Lee, Y., Lahens, N. F., Zhang, S., Bedont, J. L., Field, J. M., & Sehgal, A. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000228 · Cited by 138
Yang, L., Yang, Y., Zhang, J., Li, M., Yang, L., Wang, X., Chen, M., Zhang, H., He, B., Wang, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01983-1 · Cited by 137
The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches
Gerwing, M., Herrmann, K., Helfen, A., Schliemann, C., Berdel, W. E., Eisenblätter, M., & Wildgruber, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0169-5 · Cited by 136
Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
AbuHammad, S., Cullinane, C. M., Martin, C., Bacolas, Z., Ward, T. A., Chen, H., Slater, A. A., Ardley, K., Kirby, L., Chan, K. T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901323116 · Cited by 138
Iwata, H., Im, S.-A., Masuda, N., Im, Y.-H., Inoue, K., Rai, Y., Nakamura, R., Kim, J. H., Hoffman, J. T., Zhang, K., et al. (2017) · Journal of Global Oncology · doi:10.1200/jgo.2016.008318 · Cited by 128
Self-citationFrom Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review
Valdivia, G., Alonso‐Diez, Á., Alenza, M. D. P., & Peña, L. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.623800 · Cited by 146
“All of the latter have been approved by the EuropeanMedicines Agency (EMA) for clinical use in patients with HER-2+HBC (149).”
BackgroundShah, M., Nunes, M. R., & Stearns, V. (2018) · PubMed · Cited by 160
Brosnan, E. M., & Anders, C. K. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.35 · Cited by 138
Kurland, B. F., Peterson, L. M., Lee, J. H., Schubert, E. K., Currin, E. R., Link, J. M., Krohn, K. A., Mankoff, D. A., & Linden, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0362 · Cited by 129
Lloyd, M. R., Wander, S. A., Hamilton, E., Razavi, P., & Bardia, A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221113694 · Cited by 109
Dickler, M. N., Barry, W. T., Cirrincione, C., Ellis, M. J., Moynahan, M. E., Innocenti, F., Hurria, A., Rugo, H. S., Lake, D. E., Hahn, O. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1595 · Cited by 128
Wang, K., Russell, J. S., McDermott, J. D., Elvin, J. A., Khaira, D., Johnson, A., Jennings, T. A., Ali, S. M., Murray, M., Marshall, C. B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2568 · Cited by 124
Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity
Koch, C., Kuske, A., Joosse, S. A., Yigit, G., Sflomos, G., Thaler, S., Smit, D. J., Werner, S., Borgmann, K., Gärtner, S., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911908 · Cited by 124
“Interestingly, treatment with the CDK4/6 inhibitor Palboci-clib showed a concentration-dependent inhibition of CTC-ITB-01 growth, suggesting that the patient may have benefitted from this new line of therapy recently approved for ER + patients (Turner et al , 2015; Finn et al , 2016).”
BackgroundAre all cyclin-dependent kinases 4/6 inhibitors created equal?
Marra, A., & Curigliano, G. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0121-y · Cited by 123
Xue, Y., Meehan, B., Macdonald, E. A., Venneti, S., Wang, X. Q. D., Witkowski, L., Jelinic, P., Kong, T., Martínez, D., Morin, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-06958-9 · Cited by 128
O’Leary, B., Cutts, R. J., Huang, X., Hrebien, S., Liu, Y., André, F., Loibl, S., Loi, S., García-Murillas, I., Cristofanilli, M., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa087 · Cited by 136
“The design of the PALOMA-3 trial (NCT01942135) and clinical outcome data has been previously reported (2).”
MethodSelf-citationMechanisms of endocrine therapy resistance in breast cancer
Rasha, F. A., Sharma, M., & Pruitt, K. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111322 · Cited by 145
“However, the overall survival (OS) data was still immature during the time of publication and multiple adverse events both hematologic and non-hematologic incidences such as neutropenia, leucopenia, alopecia, nausea, fatigue were observed higher in palbociclib group compared to either letrozole- or fulvestrant-placebo…”
Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic
Galiana, I., Lozano-Torres, B., Sancho, M., Alfonso, M., Bernardos, A., Bisbal, V., Serrano, M., Martínez-Máñez, R., & Orzáez, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.045 · Cited by 115
Onesti, C. E., & Jérusalem, G. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1852934 · Cited by 128
Cancer biomarkers for targeted therapy
Liu, D. (2019) · Biomarker Research · doi:10.1186/s40364-019-0178-7 · Cited by 120
Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases
Priedigkeit, N., Watters, R. J., Lucas, P. C., Basudan, A., Bhargava, R., Horne, W. T., Kolls, J. K., Fang, Z., Rosenzweig, M. Q., Brufsky, A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.95703 · Cited by 133
Ciruelos, E., Villagrasa, P., Pascual, T., Oliveira, M., Pernas, S., Paré, L., Escrivá-de-Romaní, S., Manso, L., Adamo, B., de Dueñas, E. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0844 · Cited by 119
Groenland, S. L., Martínez-Chávez, A., van Dongen, M. G. J., Beijnen, J. H., Schinkel, A. H., Huitema, A. D. R., & Steeghs, N. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00930-x · Cited by 123
Musolino, A., Campone, M., Neven, P., Denduluri, N., Barrios, C. H., Cortés, J., Blackwell, K., Soliman, H. H., Kahán, Z., Bonnefoi, H. R., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0807-8 · Cited by 114
Self-citationKwan, T. T., Bardia, A., Spring, L. M., Giobbie‐Hurder, A., Kalinich, M., Dubash, T. D., Sundaresan, T. K., Hong, X., LiCausi, J. A., Ho, U. K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0432 · Cited by 114
Kumar, V., Alt, F. W., & Frock, R. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611882113 · Cited by 107
Liang, X., Yan, Z., Ma, W., Qian, Y., Zou, X., Cui, Y., Liu, J., & Meng, Y. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03253-8 · Cited by 117
Targeting senescence as an anticancer therapy
Bousset, L., & Gil, J. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13312 · Cited by 105
Zhang, P., Zhang, Q., Tong, Z., Sun, T., Li, W., Ouyang, Q., Hu, X., Cheng, Y., Yan, M., Pan, Y., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00172-9 · Cited by 125
Liu, D. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0819-1 · Cited by 121
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Laroche-Clary, A., Chaire, V., Algeo, M.-P., Derieppe, M.-A., Loarer, F. L., & Italiano, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0482-3 · Cited by 111
Piezzo, M., Chiodini, P., Riemma, M., Cocco, S., Caputo, R., Cianniello, D., Gioia, G. D., Lauro, V. D., Rella, F. D., Fusco, G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176400 · Cited by 119
Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies
Chaudhari, R. H., Patel, V., & Kumar, A. (2024) · Nanoscale Advances · doi:10.1039/d4na00086b · Cited by 125
Kodama, M., Kodama, T., Newberg, J. Y., Katayama, H., Kobayashi, M., Hanash, S. M., Yoshihara, K., Wei, Z., Tien, J. C., Rangel, R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705441114 · Cited by 108
O’Brien, N. A., Conklin, D. F., Beckmann, R. P., Luo, T., Chau, K., Thomas, J. D., Nulty, A. M., Marchal, C. C., Kalous, O., von Euw, E., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0290 · Cited by 116
Palbociclib in metastatic breast cancer: current evidence and real-life data
Serra, F., Lapidari, P., Quaquarini, E., Tagliaferri, B., Sottotetti, F., & Palumbo, R. (2019) · Drugs in Context · doi:10.7573/dic.212579 · Cited by 109
To clear, or not to clear (senescent cells)? That is the question
Lujambio, A. (2016) · BioEssays · doi:10.1002/bies.201670910 · Cited by 108
Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer
Khatpe, A. S., Adebayo, A. K., Herodotou, C., Kumar, B., & Nakshatri, H. (2021) · Cancers · doi:10.3390/cancers13030369 · Cited by 117
NCCN Guidelines Update: Breast Cancer
Gradishar, W. J., & Salerno, K. E. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0181 · Cited by 108
Subhan, M. A., Parveen, F., Shah, H., Yalamarty, S. S. K., Ataide, J. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15082204 · Cited by 118
Role of the androgen receptor in triple-negative breast cancer.
Rampurwala, M. M., Wisinski, K. B., & O'Regan, R. M. (2016) · PubMed · Cited by 166
Miettinen, T. P., Peltier, J., Härtlova, A., Gierliński, M., Jansen, V. M., Trost, M., & Björklund, M. (2018) · The EMBO Journal · doi:10.15252/embj.201798359 · Cited by 101
Asghar, U. S., Kanani, R., Roylance, R. R., & Mittnacht, S. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00002 · Cited by 120
The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
Law, A. M. K., Lim, E., Ormandy, C. J., & Gallego‐Ortega, D. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0404 · Cited by 120
Dieras, V. C., Rugo, H. S., Schnell, P., Gelmon, K. A., Cristofanilli, M., Loi, S., Colleoni, M. A., Lu, D. R., Mori, A., Gauthier, E. R., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy109 · Cited by 113
Self-citationComparative genomic analysis of primary tumors and metastases in breast cancer
Bertucci, F., Finetti, P., Guillé, A., Adélaïde, J., Garnier, S., Carbuccia, N., Monneur, A., Charafe‐Jauffret, E., Gonçalvès, A., Viens, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8349 · Cited by 125
Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas
Helbig, D., Ihle, M. A., Pütz, K., Tantcheva‐Poór, I., Mauch, C., Büttner, R., & Quaas, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7845 · Cited by 106
Pe, M. L., Dorme, L., Coens, C., Basch, E., Calvert, M., Campbell, A., Cleeland, C. S., Cocks, K., Collette, L., Dirven, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30418-2 · Cited by 108
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1510345 · Cited by 100
Turner, N. C., Finn, R. S., Martín, M., Im, S., DeMichele, A. M., Ettl, J., Dieras, V. C., Moulder, S., Lipatov, O. N., Colleoni, M. A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx797 · Cited by 105
Self-citationMiglietta, F., Bottosso, M., Griguolo, G., Dieci, M. V., & Guarneri, V. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100409 · Cited by 109
Parrish, K. E., Pokorny, J. L., Mittapalli, R. K., Bakken, K. K., Sarkaria, J. N., & Elmquist, W. F. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.228213 · Cited by 108
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
Ma, H., Seebacher, N. A., Hornicek, F. J., & Duan, Z. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.022 · Cited by 108
“S FDA approval for the treatment of breast cancer [14,15].”
BackgroundAhlin, C., Lundgren, C., Varro, E. E., Jirström, K., BLOMQVIST, C. P., & Fjällskog, M.-L. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4294-5 · Cited by 104
Lloyd, M. R., Spring, L. M., Bardia, A., & Wander, S. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2947 · Cited by 101
Loi, S., Dafni, U. G., Karlis, D., Polydoropoulou, V., Young, B. M., Willis, S., Long, B. C., de Azambuja, E., Sotiriou, C. P., Viale, G., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0339 · Cited by 97
Self-citationClinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
Reinert, T., Saad, E. D., Barrios, C. H., & Bines, J. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00026 · Cited by 107
Metadata
- Authors
- Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., Giorgetti, C., Randolph, S., Koehler, M., & Cristofanilli, M.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- National Cancer Center (KR)
- Institut Gustave Roussy (FR)
- The University of Melbourne (AU)
- Aichi Cancer Center Hospital (JP)
- Ludwig-Maximilians-Universität München (DE)
- German Breast Group (DE)
- Pfizer (United States) (US)
- Thomas Jefferson University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 209-219
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1464936406
- Cited by
- 1,590
- References
- 26
- Citations by year
- 2026: 67 · 2025: 142 · 2024: 117 · 2023: 109 · 2022: 127 · 2021: 142 · 2020: 172 · 2019: 123 · 2018: 169 · 2017: 193 · 2016: 179 · 2015: 49
- FWCI
- 154.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- The Medicine Forum (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, hormone receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, fulvestrant, progression-free survival, endocrine therapy resistance, neutropenia, febrile neutropenia, goserelin, metastatic breast cancer, G1/S transition, adverse events, overall survival
- MeSH terms
- Fulvestrant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Estradiol, Female, Humans, Middle Aged, Piperazines, Pyridines, Receptors, Estrogen, Receptors, Progesterone, Biomarkers, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.